Loading
Yanuki
KEYWORD TOPIC
Intellia Therapeutics Pauses CRISPR Gene-Editing Trials Due to Safety Concerns | CRISPR-Based TB Test Using Tongue Swab Developed by Tulane University | AppLovin and CRISPR Therapeutics: Recent Stock Trends and Analyst Ratings | Cathie Wood's Recession Picks: Palantir, Tesla, Crispr Poised for Growth? | Intellia Therapeutics Pauses CRISPR Gene-Editing Trials Due to Safety Concerns | CRISPR-Based TB Test Using Tongue Swab Developed by Tulane University | AppLovin and CRISPR Therapeutics: Recent Stock Trends and Analyst Ratings | Cathie Wood's Recession Picks: Palantir, Tesla, Crispr Poised for Growth?

News / Clinical Trials

Intellia Therapeutics Pauses CRISPR Gene-Editing Trials Due to Safety Concerns

Intellia Therapeutics (NASDAQ:NTLA) has temporarily paused patient dosing and screening in its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nexiguran ziclumeran (nex-z) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and...

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)
Intellia Therapeutics Pauses CRISPR Gene-Editing Trials Due to Safety Concerns Image via Intellia Therapeutics
TOPIC crispr

Health / Medical Devices

CRISPR-Based TB Test Using Tongue Swab Developed by Tulane University

Researchers at Tulane University have developed an innovative CRISPR-based tuberculosis (TB) test that utilizes a simple tongue swab for sample collection. This new approach aims to enhance community-based screenings and improve TB detectio...

Green Wave Hosts Sugar Bowl Fleet Races this Weekend

Finance / Stocks

AppLovin and CRISPR Therapeutics: Recent Stock Trends and Analyst Ratings

This article summarizes the recent stock trends and analyst ratings for AppLovin Corporation (APP) and CRISPR Therapeutics (CRSP), providing an overview for investors to stay informed.

AppLovin Corporation (APP) Is a Trending Stock: Facts to Know Before Betting on It